Researchers are re-evaluating preclinical animal models for colorectal cancer in light of advancements in precision medicine. Alternative approaches, such as ai-driven virtual cell models and human disease models, are being explored for their potential in preclinical research and drug development. The use of these new models may have implications for clinical translation and the development of new treatments.